Tests CTIM-76 in adults with recurring ovarian cancer and other solid tumors
Tests CTIM-76 in adults with advanced ovarian, testicular or endometrial cancer.
Plain-language title generated from the registry record
Registry title: A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Key facts
- Where
- Lyon, Nice Cedex 2, Rennes Cedex, Saint-Herblain Cedex, Strasbourg Cedex 2, and Villejuif, FranceSee the 6 sites
- Phase
- Phase 1
Where in France
- Centre Leon BerardLyon, FranceNot yet recruiting
- Centre Antoine LacassagneNice Cedex 2, FranceNot yet recruiting
- Centre De Lutte Contre Le Cancer Eugene MarquisRennes Cedex, FranceNot yet recruiting
- Institut De Cancerologie De L OuestSaint-Herblain Cedex, FranceNot yet recruiting
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceNot yet recruiting
- Institut Gustave RoussyVillejuif, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Context Therapeutics Inc.
- Trial code
- NCT06515613EU 2025-523968-20-00
- Record updated
- 10 November 2026
- Original description
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).Read full original descriptionShow less
A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Inclusion: Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer; Participants with measurable disease per RECIST 1.1; ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks; Participants with adequate organ function.
Exclusion: Concurrent participation in another investigational clinical trial; Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression; Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study.